Kate Hermans - Jan 27, 2023 Form 4 Insider Report for Ambrx Biopharma Inc. (AMAM)

Role
Director
Signature
/s/ Sonja Nelson, Attorney-in-Fact for Kate Hermans
Stock symbol
AMAM
Transactions as of
Jan 27, 2023
Transactions value $
$0
Form type
4
Date filed
1/31/2023, 05:07 PM
Previous filing
Jan 3, 2023
Next filing
Jun 9, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMAM Stock Option (right to buy) Disposed to Issuer -210K -100% 0 Jan 27, 2023 Ordinary Shares 210K $0.38 Direct F1, F2, F3
transaction AMAM Stock Option (right to buy) Award +210K 210K Jan 27, 2023 Ordinary Shares 210K $0.28 Direct F1, F2, F3
transaction AMAM Stock Option (right to buy) Disposed to Issuer -105K -100% 0 Jan 27, 2023 Ordinary Shares 105K $0.43 Direct F2, F3, F4
transaction AMAM Stock Option (right to buy) Award +105K 105K Jan 27, 2023 Ordinary Shares 105K $0.28 Direct F2, F3, F4
transaction AMAM Stock Option (right to buy) Disposed to Issuer -210K -100% 0 Jan 27, 2023 Ordinary Shares 210K $0.35 Direct F2, F3
transaction AMAM Stock Option (right to buy) Award +210K 210K Jan 27, 2023 Ordinary Shares 210K $0.28 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares subject to the option vest in thirty-six equal monthly installments following June 30, 2022.
F2 The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents seven Ordinary Shares of the Issuer.
F3 The option held by the reporting person was amended to reduce the exercise price.
F4 The Ordinary Shares subject to the option will vest on the earlier of (i) July 8, 2023, or (ii) the day immediately prior to the date of the next Annual Grant Date as defined in the Company's Non-Employee Director Compensation Policy.